Dosage and administration
One bottle of Selank contains 60 drops, each having 75 mcg of the active ingredient. The average dose is 2-3 drops in each nostril. If there is a need to take more a 15-minut interval should be taken between the administrations. Semax should be taken up to 3 times per day.
With the purpose of anxiety reduction Selank should be taken twice per day, 2-3 drops in each nostril for a period of 10 to 14 days.
Depending on the chosen dosage one bottle is sufficient for a course of 3 - 7 days.
Extremely rare individual allergic reactions
Overdose effects have not been observed even when increasing the active doses by hundreds of times.
Keep in a dark place under the temperature of less than 10 C (50 F) for two years.
Note: Being Peptides, Semax and Selank should not be exposed to high temperatures for long periods of time. They can however be safely kept at the room temperature for period of less than a month. Each bottle also contains methylparaben (0.1%), which works as a preservative.
Country of Manufacture: Russia
Availability: in stock
2 week course is 2 Bottles 3ml/pack 0.15% - Save with the volume discount!
In the beginning of 80-s Russian Academy of Science became interested in testing various peptides. A breakthrough came in 1995, when one of them - Tafcin - appeared to have anxiolytic effects in animals. Over the next decade researchers managed to develop Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) a synthetic analogue of the peptide that was able to have the most pronounced anxiolitic properties. The clinical trials lasted up to 2009, when Selank was finally brought to the market under the brand name SELANK® 0,15%.
- Anxiety-asthenic disorders
- Stress and pressure at school or at work
Country of Manufacture: Russia
- Zozulya et al (2001) The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activityhttps://www.ncbi.nlm.nih.gov/pubmed/11550013
- Kost et al (2001) Semax and selank inhibit the enkephalin-degrading enzymes from human serumhttps://www.ncbi.nlm.nih.gov/pubmed/11443939
- Sokolov et al (2002) Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactionshttps://www.ncbi.nlm.nih.gov/pubmed/12432865
- Kozlovskaya et al (2003) Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stresshttps://www.ncbi.nlm.nih.gov/pubmed/14969422
- I. Kozlovkii, N. Danchev (2003) The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in ratshttps://www.ncbi.nlm.nih.gov/pubmed/14552529
- T. Ganshina, I. Kozlovskii (2005) Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in catshttps://www.ncbi.nlm.nih.gov/pubmed/16193654
- Semenova et al (2007) Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogenyhttps://www.ncbi.nlm.nih.gov/pubmed/18683497
- Sarkisova et al (2008) Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c micehttps://www.ncbi.nlm.nih.gov/pubmed/18661785
- Zozulia et al (2008) Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurastheniahttps://www.ncbi.nlm.nih.gov/pubmed/18454096
- Uchakina et al (2008) Immunomodulatory effects of selank in patients with anxiety-asthenic disordershttps://www.ncbi.nlm.nih.gov/pubmed/18577961
- Medvedev et al (2014) A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disordershttps://www.ncbi.nlm.nih.gov/pubmed/25176261
- Kolomin et al (2014) The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank actionhttps://www.ncbi.nlm.nih.gov/m/pubmed/24291245/ Medvedev et al (2015) Optimization of the treatment of anxiety disorders with selankhttps://www.ncbi.nlm.nih.gov/pubmed/26356395
- Volkova et al (2016) Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmissionhttps://www.ncbi.nlm.nih.gov/pubmed/26924987
- Kaisan et al (2017) Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Ratshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322660/
- Filatova et al (2017) GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cellshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328971/
- Fomenko et al (2017) Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stresshttps://www.ncbi.nlm.nih.gov/pubmed/28853100
- Slominsky et al (2017) Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonismhttps://www.ncbi.nlm.nih.gov/pubmed/28702721